Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Phase Ib/2 Study of Nelmastobart in Combination With Trifluridine/Tipiracil and Bevacizumab in Metastatic/Recurrent Colorectal Cancer Patients With Resistance or Intolerance to Oxaliplatin and Irinotecan-based Chemotherapy

NCT06873763 is registered in ClinicalTrials.gov with STCube, Inc. as lead sponsor.

NCT NCT06873763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06873763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Phase Ib/2 Study of Nelmastobart in Combination With Trifluridine/Tipiracil and Bevacizumab in Metastatic/Recurrent Colorectal Cancer Patients With Resistance or Intolerance to Oxaliplatin and Irinotecan-based Chemotherapy
Lead sponsor
STCube, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 9, 2025
Completion date
March 31, 2027
Enrollment
52 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer (crc), recurrent colorectal cancer